Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
$29.25
$30.05
$27.07
▼
$35.99
$20.08B0.722.52 million shsN/A
Novavax, Inc. stock logo
NVAX
Novavax
$8.52
-2.7%
$10.54
$6.20
▼
$13.39
$1.41B2.656.23 million shs4.64 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
0.00%0.00%0.00%0.00%-2.66%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-20.96%-33.54%+5.84%+18.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
$29.25
$30.05
$27.07
▼
$35.99
$20.08B0.722.52 million shsN/A
Novavax, Inc. stock logo
NVAX
Novavax
$8.52
-2.7%
$10.54
$6.20
▼
$13.39
$1.41B2.656.23 million shs4.64 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
0.00%0.00%0.00%0.00%-2.66%
Novavax, Inc. stock logo
NVAX
Novavax
0.00%-20.96%-33.54%+5.84%+18.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
0.00
N/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
2.20
Hold$12.3344.76% Upside

Current Analyst Ratings Breakdown

Latest EDR and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingBuy$18.00 ➝ $16.00
11/2/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingSell (D)
10/27/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingOverweight
10/15/2026
Novavax, Inc. stock logo
NVAX
Novavax
Reiterated RatingSell$7.00 ➝ $8.00
(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
$7.11B2.82$0.57 per share50.90$16.65 per share1.76
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.25$3.51 per share2.43($0.79) per share-10.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
$356.52M-$2.66N/A21.99N/A-8.34%3.79%1.94%N/A
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$0.46N/AN/AN/A-18.64%-14.82%-7.55%N/A

Latest EDR and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3460-$0.19+$0.1560-$0.19$50.42 million$68.30 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
$0.240.82%N/AN/A 1 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
0.28
0.63
0.63
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.15
2.09

Institutional Ownership

CompanyInstitutional Ownership
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
74.99%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
63.90%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Endeavor Group Holdings, Inc. stock logo
EDR
Endeavor Group
1,120686.35 million246.98 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
749165.01 million162.37 millionOptionable

Recent News About These Companies

Novavax (NASDAQ:NVAX) Shares Down 9.4% - What's Next?
Novavax (NVAX) stock trades up, here is why
Novavax (NASDAQ:NVAX) Upgraded at Wall Street Zen
Novavax Earnings Call Signals Stronger Growth Ahead
Novavax Q3 Earnings Call Highlights
Novavax pushes profitability target to 2029, shares dip

New MarketBeat Followers Over Time

Media Sentiment Over Time

Endeavor Group stock logo

Endeavor Group NYSE:EDR

Endeavor Group Holdings, Inc. operates as a sports and entertainment company in the United States, the United Kingdom, and internationally. It operates through four segments: Owned Sports Properties; Events, Experiences & Rights; Representation; and Sports Data & Technology. The Owned Sports Properties segment operates a portfolio of sports properties, including Ultimate Fighting Championship, World Wrestling Entertainment, Inc., Professional Bull Rider, and Euroleague. The Events, Experiences & Rights segment provides services to live events, including sporting events, fashion, art fairs and music, culinary, lifestyle festivals, and major attractions. This segment also distributes sports programming; and operates events on behalf of third parties. The Representation segment offers services to talent across entertainment, sports, and fashion, such as actors, directors, writers, athletes, models, musicians, and other artists in various mediums. This segment provides brand strategy, marketing, advertising, public relations, analytics, digital, activation, and experiential services to corporate and other clients; intellectual property licensing services to a portfolio of entertainment, sports, and consumer product brands, including clients' licensing logos, trade names, and trademarks representation. The Sports Data & Technology segment delivers live streaming and data feeds for sports events to sportsbooks, rightsholders, and media partners, as well as on-demand virtual sports products and front-end solutions, including the UFC Event Centre. This segment also specializes in betting engine products, services and technology, and bet processing, as well as trading, pricing, and risk management tools; player account and wallet solutions; front-end user experiences and user interfaces; and content offerings, such as BetBuilder, DonBest pricing feeds, and a sports content aggregation platform. The company was founded in 1898 and is based in Beverly Hills, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$8.52 -0.24 (-2.74%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$8.52 0.00 (-0.05%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.